Browse EX-10 agreements

Root, Inc.

Non-Employee Director Compensation Policy

Adopted April 30, 2026

Each member of the Board of Directors (the “Board”) of Root, Inc. (the “Company”) who is not an employee of the Company (each, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “DirectorCompensation Policy”) for his or her Board service, subject to the terms and conditions set forth herein.

This Director Compensation Policy may be amended or modified, or any provision of it waived, at any time in the sole discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”).

Notwithstanding the foregoing, the Board or Compensation Committee may make supplemental grants to Non-Employee Directors in its discretion.

Annual Retainers

…

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT(“Amendment”)is made and entered into effective as of this 4thday of August, 2026 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Alex Levit(“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.”

    WHEREAS, the Company and Executive are parties to an employment agreement dated August 13, 2021 (the “Employment Agreement”); and

    WHEREAS, the Parties wish to amend the Employment Agreement with this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants contained and incorporated herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby expressly covenant and agree as follows:

1.Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

…

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT(“Amendment”)is made and entered into effective as of this 4thday of August, 2026 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Jennifer Minai-Azary (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.”

    WHEREAS, the Company and Executive are parties to an employment agreement dated November 1, 2021 (the “Employment Agreement”); and

    WHEREAS, the Parties wish to amend the Employment Agreement with this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants contained and incorporated herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby expressly covenant and agree as follows:

1.Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

…

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT(“Amendment”)is made and entered into effective as of this 4thday of August, 2026 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Karen Chagin, M.D. (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.”

    WHEREAS, the Company and Executive are parties to an employment agreement dated June 9, 2025 (the “Employment Agreement”); and

    WHEREAS, the Parties wish to amend the Employment Agreement with this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants contained and incorporated herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby expressly covenant and agree as follows:

1.Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

…

FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT(“Amendment”)is made and entered into effective as of this 4thday of August, 2026 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Martin Lehr (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.”

    WHEREAS, the Company and Executive are parties to an amended and restated employment agreement dated October 22, 2021 (the “Employment Agreement”); and

    WHEREAS, the Parties wish to amend the Employment Agreement with this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants contained and incorporated herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby expressly covenant and agree as follows:

1.Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

…

April 17, 2026

David Day

By Email

Dear David:

You have indicated that you intend to retire from your employment with Magnite, Inc.(the “Company”). This letter (the “Agreement”) confirms the agreement between you and the Company regarding your continued employment and provision of services to the Company pending your retirement.

1.Transition Period. Subject to the terms and conditions of this Agreement, it is expected that you will continue to serve as the Company’s Chief Financial Officer through September 30, 2026. Upon cessation of your role as Chief Financial Officer, and continuing through May 31, 2027 (as may be extended in accordance with this Agreement, the “Transition End Date”), it is expected that you will remain employed by the Company, with the title Advisor to the CEO and CFO, reporting to the Chief Executive Officer (the period in which you commence service as Advisor to the CEO and CFO through the Transition End Date shall be referred to as the “Transition Period”).

…

Transition Agreement This Transition Agreement (the “Agreement”) by and between Cardlytics, Inc. (the “Company”) and Nicholas Lynton (“You” or “Your”) (collectively the “Parties”) is entered into and effective as of May 10, 2026 (the “Effective Date”). 1.​ Terms of Transition. a.​ At-Will Employment. The Company shall continue to employ You on an at-will basis through July 3, 2026 (the “Separation Date”). The time period from the Effective Date through the Separation Date shall be referred to herein as the “Transition Term.” During the Transition Term, either You or the Company may terminate Your employment at any time, with or without cause or notice, and in the event such a termination occurs, Your last day of employment shall be considered the Separation Date and the end of the Transition Term. While you remain employed by the Company, you shall retain the title and serve in the role of Chief Legal and Privacy Officer (“CLO”), unless a new CLO is appointed prior to your last day of employment, in which case you shall assume the title of and serve in the role of Company Advisor and

…

GOODRXHOLDINGS,INC.

NON-EMPLOYEEDIRECTORCOMPENSATIONPROGRAM

Third AmendedandRestatedeffectiveasofMay 27, 2026

Eligible Directors (as defined below) on the board of directors (the “Board”) of GoodRx

Holdings,Inc.(the“Company”)shallbeeligibletoreceivecashandequitycompensationassetforthin

this Non- Employee Director Compensation Program (this “Program”). The cash and equity

compensationdescribedinthisProgramshallbepaidorbemade,asapplicable,automaticallyassetforth

hereinandwithoutfurther action of the Board, to eachmember of the Board who is not an employee of

the Company or any of its parents, affiliates or subsidiaries and who is determined by the Board to be

eligibletoreceivecompensationunderthisProgram(each,an“EligibleDirector”),whomaybeeligible

to receive such cash or equity compensation, unless such Eligible Director declines the receipt of such

cash or equity compensation by written notice to the Company.

This Program, as amended, shall become effective as of the date first set forth above (the

…

FOURTH AMENDMENT TO LEASE

This FOURTH AMENDMENT TO LEASE (this "Amendment") is dated as of May 19, 2026 (the "Effective Date"), by and between MADISON-OFC ONE MAIN PLACE OR LLC, a Delaware limited liability company ("Landlord"), and SCHRÖDINGER, INC., a Delaware corporation ("Tenant").

R E C I T A L S :

A.Landlord (as successor-in-interest to KBSII One Main Place, LLC, and prior thereto One Main Place Portland – Oregon, Inc.), and Tenant are parties to that certain Lease dated as of July 30, 2008 (the "OriginalLease"), as amended by that certain First Amendment to Office Lease dated as of October 27, 2014 (the "First Amendment"), that certain Second Amendment to Office Lease dated as of December 10, 2018 (the "Second Amendment") and that certain Third Amendment dated as of May 6, 2021 (the "Third Amendment", and together with the Original Lease, the First Amendment and the Second Amendment, collectively, the "Lease"), pursuant to which Tenant leases from Landlord certain premises (collectively, the "Premises") consisting of (i) that certain space commonly known as "Suite 1300" ("S

…

AMENDMENT #2

TO THE INDEPENDENT CONTRACTOR AGREEMENT

This Amendment (“Amendment 2”) is effective as of the date of the last signature (“Amendment 2 Effective Date”) and modifies the Independent Contractor Agreement by and between Gates Ventures, LLC (“Company”) and Schrödinger, Inc. (“Contractor” or “Schrödinger”) dated June 16, 2020, amended August 14, 2023 (the “Agreement”).

WHEREAS, the parties hereto wish to amend the Agreement to amend certain provisions of the Agreement; and

WHEREAS, capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

NOW THEREFORE, in consideration of the terms and conditions set forth herein the parties agree to amend the Agreement as follows:

1.Term and Termination of Exhibit A-1 (Statement of Work #2 and Fees for Services) is hereby deleted and replaced with the following:

…

SCHRÖDINGER, INC.

2022 EQUITY INCENTIVE PLAN

1. Purpose

The purpose of this 2022 Equity Incentive Plan (the “Plan”) of Schrödinger, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the “Board”).

…

June4,2026

Dear Scott:

Asyouhaveindicated youwillretireuponthe20thAnniversary ofFreshpet.Inc.(the"Company"), thisletter willconfirm thefollowing termsinconnection withyour separation ofemployment from Freshpet, Inc.(the"Company").TheCompany andyouagreethatthisletter(the"Agreement") represents thefullandcompleteagreement concerning your separation ofemployment fromthe Company.

1)Separation and Continuity Period.You will separate employment from the Company on October 20, 2026 (or such earlier date of your actual employment termination, the "Separation Date").

a)During theperiod beginning now and ending ontheSeparation Date (the"Continuity Period"), you willmakeyourself available asneeded toensure a smooth transition.

…